Adjuvant Pembrolizumab (NSCLC), Elacestrant, & Pirtobrutinib
OncoPharm
00:00
Overall Survival and Treatment Sequencing for ER+ Disease
John discusses interim OS differences, available subsequent options like CDK4/6 inhibitors or chemotherapy, and need for mature OS.
Play episode from 10:31
Transcript
